Paradigm Biocapital Advisors LP Alpine Immune Sciences, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Alpine Immune Sciences, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,121,163 shares of ALPN stock, worth $0. This represents 3.15% of its overall portfolio holdings.
Number of Shares
2,121,163
Previous 3,176,743
33.23%
Holding current value
$0
Previous $60.5 Million
38.87%
% of portfolio
3.15%
Previous 3.14%
Shares
8 transactions
Others Institutions Holding ALPN
# of Institutions
186Shares Held
62MCall Options Held
158KPut Options Held
199K-
Decheng Capital LLC Menlo Park, CA8.32MShares$044.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.78MShares$02.76% of portfolio
-
Black Rock Inc. New York, NY3.58MShares$00.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.13MShares$06.52% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.08MShares$00.01% of portfolio
About ALPINE IMMUNE SCIENCES, INC.
- Ticker ALPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,006,700
- Description
- Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...